Key Insights on Gross Profit: Bio-Techne Corporation vs Pharming Group N.V.

Biotech Giants: A Decade of Financial Growth Compared

__timestampBio-Techne CorporationPharming Group N.V.
Wednesday, January 1, 201425141100021595165
Thursday, January 1, 20153072770006590427
Friday, January 1, 201633665900011768542
Sunday, January 1, 201737454100092587038
Monday, January 1, 2018432143000129203843
Tuesday, January 1, 2019473491000165412447
Wednesday, January 1, 2020483194000203056430
Friday, January 1, 2021632850000169670071
Saturday, January 1, 2022756496000188060000
Sunday, January 1, 2023769815000220104000
Monday, January 1, 2024769725000
Loading chart...

Unlocking the unknown

A Tale of Two Biotech Giants: Bio-Techne Corporation vs. Pharming Group N.V.

In the dynamic world of biotechnology, financial performance is a key indicator of a company's health and potential. Over the past decade, Bio-Techne Corporation has consistently outperformed Pharming Group N.V. in terms of gross profit. From 2014 to 2023, Bio-Techne's gross profit surged by over 200%, peaking in 2023 with a remarkable 770 million USD. In contrast, Pharming Group N.V. experienced a more modest growth, with its gross profit increasing by approximately 900% over the same period, reaching 220 million USD in 2023.

This stark difference highlights Bio-Techne's robust market strategy and operational efficiency. However, Pharming's rapid growth rate, despite its smaller base, suggests a promising trajectory. As we look to the future, the absence of data for 2024 leaves room for speculation on how these biotech titans will continue to evolve.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025